Live virus immunization after orthotopic liver transplantation

Area of Science:

• Pediatric immunology
• Transplant medicine
• Vaccinology

Background:

• Viral infections pose significant risks to pediatric solid organ transplant recipients, especially infants lacking full immunization.
• Standard practice often withholds live virus vaccines from transplant patients, despite emerging research.
• Previous small studies explored measles, mumps, and rubella (MMR) and varicella vaccine administration post-transplant.

Purpose of the Study:

• To evaluate the safety and immunogenicity of primary measles, mumps, and rubella (MMR) and varicella immunization in pediatric liver transplant recipients.
• To assess serologic response rates and identify any adverse events associated with live virus vaccination in this vulnerable population.

Main Methods:

• Retrospective analysis of medical records from selected pediatric liver transplant recipients.
• Assessment of serologic immunity following administration of the MMR vaccine and/or the varicella vaccine.
• Documentation of adverse events and the need for multiple vaccine doses.

Main Results:

• Measles immunity was achieved in 73% (19/26) of children after MMR vaccination, with 18 requiring multiple doses.
• Varicella vaccine resulted in seroconversion in 64.5% (20/31) of children, with seven requiring multiple doses.
• Adverse effects were comparable to those observed in the general population.

Conclusions:

• Live virus immunization with MMR and varicella vaccines is safe and immunogenic in a selected group of pediatric liver transplant recipients.
• Vaccination can be a viable strategy to prevent otherwise preventable infections in this population.
• Further research may support broader live virus vaccine administration in pediatric transplant recipients.